Burkehill Global Management’s Xenon Pharmaceuticals XENE Stock Holding History

Burkehill Global Management’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.04M	Hold	100,000	–	–	0.22%	65
2026 Q1	$5.82M	Buy	+100,000	New	+$4.61M	0.29%	70

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Burkehill Global Management's XENE Position: Q2 2026 in Review

Burkehill Global Management held its Xenon Pharmaceuticals (XENE) position steady in Q2 2026 at 100,000 shares worth $6.04M. The position accounts for 0.22% of the portfolio, ranked #65.

Burkehill Global Management first reported a position in XENE in Q1 2026 and has held it in 2 quarters since. 316 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

Burkehill Global Management held 100,000 shares of Xenon Pharmaceuticals worth $6.04M as of Q2 2026.
Burkehill Global Management left its Xenon Pharmaceuticals share count unchanged in Q2 2026.
Xenon Pharmaceuticals made up 0.22% of Burkehill Global Management's portfolio in Q2 2026, its #65 holding.
Burkehill Global Management first reported a position in Xenon Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
316 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Burkehill Global Management's 13F filing for Q2 2026, filed 14 Aug 2026.